Literature DB >> 21338640

Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection.

Diala El-Maouche1, Shruti H Mehta, Catherine Sutcliffe, Yvonne Higgins, Michael S Torbenson, Richard D Moore, David L Thomas, Mark S Sulkowski, Todd T Brown.   

Abstract

BACKGROUND & AIMS: To evaluate the prevalence and risk factors for low bone mineral density (BMD) in persons co-infected with HIV and Hepatitis C.
METHODS: HIV/HCV co-infected study participants (n=179) were recruited into a prospective cohort and underwent dual-energy X-ray absorptiometry (DXA) within 1 year of a liver biopsy. Fibrosis staging was evaluated according to the METAVIR system. Osteoporosis was defined as a T-score ≤-2.5. Z-scores at the total hip, femoral neck, and lumbar spine were used as the primary outcome variables to assess the association between degree of liver disease, HIV-related variables, and BMD.
RESULTS: The population was 65% male, 85% Black with mean age 50.3 years. The prevalence of osteoporosis either at the total hip, femoral neck, or lumbar spine was 28%, with 5% having osteoporosis of the total hip, 6% at the femoral neck, 25% at the spine. The mean Z-scores (standard deviation) were -0.42 (1.01) at the total hip, -0.16 (1.05) at the femoral neck, and -0.82 (1.55) at the lumbar spine. In multivariable models, controlled HIV replication (HIV RNA <400 copies/ml vs. ≥400 copies/ml) was associated with lower Z-scores (mean ± standard error) at the total hip (-0.44 ± 0.17, p = 0.01), femoral neck (-0.59 ± 0.18, p = 0.001), and the spine (-0.98 ± 0.27, p = 0.0005). There was no association between degree of liver fibrosis and Z-score.
CONCLUSIONS: Osteoporosis was very common in this population of predominately African-American HIV/HCV co-infected patients, particularly at the spine. Lower BMD was associated with controlled HIV replication, but not liver disease severity.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21338640      PMCID: PMC3113457          DOI: 10.1016/j.jhep.2011.01.035

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  34 in total

1.  Racial differences in pre- and postmenopausal bone homeostasis: association with bone density.

Authors:  D E Meier; M M Luckey; S Wallenstein; R H Lapinski; B Catherwood
Journal:  J Bone Miner Res       Date:  1992-10       Impact factor: 6.741

2.  Disparities in osteoporosis screening between at-risk African-American and white women.

Authors:  Redonda G Miller; Bimal H Ashar; Jennifer Cohen; Melissa Camp; Carmen Coombs; Elizabeth Johnson; Christine R Schneyer
Journal:  J Gen Intern Med       Date:  2005-09       Impact factor: 5.128

Review 3.  Evaluation and management of osteoporosis in liver disease.

Authors:  J Eileen Hay; Maureen M J Guichelaar
Journal:  Clin Liver Dis       Date:  2005-11       Impact factor: 6.126

4.  Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection.

Authors:  Ingolf Schiefke; Andreas Fach; Marcus Wiedmann; Andreas-V Aretin; Eva Schenker; Gudrun Borte; Manfred Wiese; Joachim Moessner
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

Review 5.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.

Authors:  Todd T Brown; Roula B Qaqish
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

6.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

7.  Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study.

Authors:  Changhai Ding; Venkat Parameswaran; Ray Udayan; John Burgess; Graeme Jones
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

8.  Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system.

Authors:  Virginia A Triant; Todd T Brown; Hang Lee; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2008-07-01       Impact factor: 5.958

9.  Predictors of fractures in early rheumatoid arthritis.

Authors:  B A Michel; D A Bloch; J F Fries
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

10.  Race/ethnic differences in bone mineral density in men.

Authors:  A B Araujo; T G Travison; S S Harris; M F Holick; A K Turner; J B McKinlay
Journal:  Osteoporos Int       Date:  2007-03-06       Impact factor: 5.071

View more
  14 in total

Review 1.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

2.  Bone alterations associated with HIV.

Authors:  Amy H Warriner; Michael Mugavero; E Turner Overton
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

3.  Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.

Authors:  Kazuyo Takeda; Rewati Adhikari; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

Review 4.  Classical and emerging roles of vitamin D in hepatitis C virus infection.

Authors:  Julio A Gutierrez; Neil Parikh; Andrea D Branch
Journal:  Semin Liver Dis       Date:  2011-12-21       Impact factor: 6.115

5.  Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.

Authors:  E Redondo-Cerezo; F Casado-Caballero; J L Martin-Rodriguez; J Hernandez-Quero; F Escobar-Jimenez; J L Gonzalez-Calvin
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

Review 6.  Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.

Authors:  Roger Bedimo; Naim M Maalouf; Vincent Lo Re
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

7.  Hip bone geometry in HIV/HCV-co-infected men and healthy controls.

Authors:  V Walker Harris; C G Sutcliffe; A B Araujo; G R Chiu; T G Travison; S Mehta; M S Sulkowski; Y Higgins; D L Thomas; A S Dobs; T J Beck; T T Brown
Journal:  Osteoporos Int       Date:  2011-09-08       Impact factor: 4.507

8.  Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Authors:  Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

9.  Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV-HCV coinfection.

Authors:  Diala El-Maouche; Shruti H Mehta; Catherine G Sutcliffe; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski; Todd T Brown
Journal:  Antivir Ther       Date:  2012-08-07

10.  In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.

Authors:  Andrea D Branch; Minhee Kang; Kimberly Hollabaugh; Christina M Wyatt; Raymond T Chung; Marshall J Glesby
Journal:  Am J Clin Nutr       Date:  2013-06-05       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.